No one can cure ALS today, but the idea that nothing can be done is outdated and harmful. A combination of approved medications, breathing support, aggressive nutritional management, coordinated specialist care, and carefully chosen exercise can slow functional decline and extend survival, in some cases by years rather than months. The disease still varies enormously from person to person, and newer therapies targeting specific genetic forms of ALS are beginning to change what “treatment” even means for a subset of patients.
Approved Medications and What They Actually Do
Riluzole, approved in the mid-1990s, remains the most widely prescribed drug for ALS worldwide. It works by dampening excessive glutamate signaling, which is thought to contribute to motor neuron damage. In randomized controlled trials and subsequent meta-analyses, riluzole extended median survival by roughly two to three months and raised the chance of surviving an additional year by about nine percent. Those numbers sound modest, but real-world data from clinical databases paint a more encouraging picture: across ten ALS registries, riluzole therapy was associated with survival improvements exceeding 19 months in the broader patient population.1PubMed Central. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis The gap between trial data and real-world data likely reflects the fact that people in clinical practice take riluzole alongside other supportive interventions, amplifying the benefit.
Edaravone, an antioxidant that targets free-radical damage to motor neurons, is the other approved option. It was initially shown to slow functional decline in a carefully selected group of early-stage patients. Longer-term data using an oral formulation, compared against matched historical controls, showed that treated patients lost about eight points on the standard ALS functional rating scale over 48 weeks, versus roughly 14 points for untreated patients. A broader analysis showed a restricted mean survival time improvement of about seven months.2PubMed Central. Analysis of Long‐Term Function and Survival of Edaravone Oral Suspension–Treated Patients With Amyotrophic Lateral Sclerosis Using PRO‐ACT Data as Historical Placebo Controls More recently, sodium phenylbutyrate-taurursodiol (sold as Relyvrio) was granted accelerated approval in the U.S. in 2022, though the manufacturer voluntarily withdrew it in 2024 after a larger confirmatory trial failed to show benefit. That episode underscores how hard it remains to find drugs that work reliably across the full spectrum of ALS.
Breathing Support as a Survival Tool
Respiratory failure is the leading cause of death in ALS. The muscles that control breathing weaken progressively, often before you notice obvious shortness of breath. Noninvasive ventilation, delivered through a mask that assists your breathing, is one of the most powerful interventions available and the one most consistently linked to longer survival.
A large matched-cohort study found that people using noninvasive ventilation had a 26 percent lower rate of death compared with matched patients who did not use it. Among people with limb-onset ALS specifically, the reduction was 37 percent. The benefit was clearest when people used the device for at least four hours a day.3PubMed Central. Noninvasive Ventilation Use Is Associated with Better Survival in Amyotrophic Lateral Sclerosis A randomized trial showed a median survival benefit of 205 days in people with relatively preserved bulbar (mouth and throat) function, along with improved quality of life that was maintained for most of that extra time. For people with severe bulbar impairment, the survival benefit was less clear, though some quality-of-life measures still improved.4The Lancet Neurology. Non-invasive ventilation in amyotrophic lateral sclerosis: indications and effect on quality of life
Getting the settings right and sticking with the device matters enormously. A systematic review emphasized that the benefits of noninvasive ventilation depend on optimizing both the ventilation parameters and the patient’s adherence.5European Respiratory Journal. The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review Diaphragm pacing, a surgical alternative that stimulates the diaphragm electrically, has not fared well in ALS. A meta-analysis found it was associated with higher mortality and no quality-of-life advantage compared with mechanical ventilation in ALS patients.6PubMed. Diaphragm pacing compared with mechanical ventilation in patients with chronic respiratory failure caused by diaphragmatic dysfunction: a systematic review and meta-analysis
Keeping Weight Stable and Getting Enough Calories
Weight loss in ALS is dangerous. It happens for multiple reasons at once: swallowing becomes difficult, appetite drops, and the body itself burns more energy than expected. Roughly half of ALS patients show hypermetabolism, meaning their resting energy expenditure is significantly elevated even when muscle mass is declining.7PubMed. Hypermetabolism in ALS patients: an early and persistent phenomenon Higher body fat appears to be a protective factor for survival, while excess weight loss is strongly linked to shorter survival.8PubMed Central. What is “Hyper” in the ALS Hypermetabolism?
When swallowing deteriorates to the point where eating is unsafe or insufficient, a feeding tube placed through the abdominal wall into the stomach (a PEG tube) becomes the standard intervention. Studies show weight stabilization or gain after PEG placement, and data from gastrostomy-fed patients indicate that maintaining muscle mass around the upper arm lowers death risk by about ten percent per centimeter of arm circumference in the first three months of tube feeding.9PubMed Central. Nutrition and Survival of Endoscopic Gastrostomy-Fed Patients with Amyotrophic Lateral Sclerosis The timing of PEG placement matters: patients who had already lost more than ten percent of their healthy body weight or whose lung capacity was below 65 percent had worse outcomes after the procedure.10PubMed. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS The takeaway is that acting early, before severe weight loss and respiratory decline, gives the best chance of benefit.
Why Coordinated Specialist Care Adds Months
ALS affects nearly every system in the body over time: movement, breathing, swallowing, communication, sometimes cognition. Managing all of these through a single general neurologist, however dedicated, is less effective than working with a team of specialists who see ALS patients regularly. This is not just an intuitive claim; it has hard numbers behind it.
A population-based study in Ireland found that patients attending a dedicated multidisciplinary ALS clinic survived a median of 7.5 months longer than those seen in general neurology clinics. One-year mortality dropped by about 30 percent, and the benefit was especially striking for people with bulbar-onset disease, whose prognosis improved by nearly ten months.11PubMed Central. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000 A Belgian study confirmed the survival advantage, finding that multidisciplinary follow-up significantly prolonged survival overall, with the effect driven primarily by spinal-onset patients in that cohort.12PubMed. Specialized multidisciplinary care improves ALS survival in Belgium: a population-based retrospective study Data from Japan found that multidisciplinary care also reduced emergency hospitalizations, suggesting that proactive management catches problems before they become crises.13PubMed. Multidisciplinary clinic contributes to the decreasing trend in the number of emergency hospitalizations for amyotrophic lateral sclerosis in Japan
These clinics typically bring together neurologists, respiratory therapists, speech-language pathologists, dietitians, physical and occupational therapists, social workers, and palliative care specialists. The survival advantage probably comes not from any single intervention but from the cumulative effect of every problem being caught earlier and managed more aggressively.
Exercise Without Overdoing It
For decades, people with ALS received cautious or contradictory advice about physical activity. The fear was that exercising damaged motor neurons could accelerate their death. The evidence now leans in favor of moderate exercise, though the word “moderate” is doing important work in that sentence.
A systematic review and meta-analysis found that exercise interventions significantly improved overall function and walking distance in ALS patients. Resistance training was the most effective type for preserving daily function, while aerobic exercise was best for maintaining lung capacity. Exercise did not, however, significantly improve fatigue or most respiratory pressure measures.14PubMed Central. The effect of exercise intervention on amyotrophic lateral sclerosis: a systematic review and meta-analysis A separate meta-analysis found moderate-quality evidence supporting active exercise for preserving function on standard ALS rating scales.15PubMed Central. Exercises and Brain Stimulation to Preserve Function in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis
One of the earliest randomized trials on the topic showed that a moderate daily exercise program slowed deterioration on functional and spasticity scales at three months, though the difference faded by six months.16PubMed. The value of muscle exercise in patients with amyotrophic lateral sclerosis The pattern across studies seems consistent: exercise helps maintain what you have for longer, rather than building new capacity. Working with a physical therapist who understands ALS is key, because pushing too hard can cause the opposite effect, accelerating fatigue in already-weakened muscle groups.
Why Some People Live Much Longer Than Others
The typical figure cited for ALS survival is two to five years from symptom onset, but this average conceals enormous variation. Some people decline rapidly over months; others live a decade or more. Understanding what separates these groups is one of the most active areas of ALS research.
A large meta-analysis identified 25 factors that predict how long someone with ALS is likely to survive. The strongest predictors of a worse outcome included high levels of neurofilament light chain (a protein released when nerve fibers break down), co-occurring frontotemporal dementia, rapid functional decline early on, and respiratory-onset disease. Factors predicting longer survival included predominantly lower or upper motor neuron patterns, higher baseline function scores, and a longer delay between first symptoms and diagnosis.17PubMed Central. Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis
A cohort study of long-term survivors found they tended to be younger at onset, more likely male, and more likely to have spinal rather than bulbar onset. Among long-survivors, 75 percent had spinal onset compared with 59 percent of those who did not survive as long.18PubMed Central. Understanding Long-Term Survival in ALS: A Cohort Study on Subject Characteristics and Prognostic Factors Co-occurring frontotemporal dementia, which involves behavioral changes and cognitive decline alongside motor symptoms, carries a markedly worse prognosis with a hazard ratio close to three times the baseline risk.17PubMed Central. Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis Clinicians are increasingly urged to screen for frontotemporal dementia early, since it may precede obvious motor symptoms and its presence changes treatment planning.19PubMed Central. Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: A Case Report and Clinical Insights
Gene-Targeted Treatments
About five to ten percent of ALS cases are familial, meaning they run in families with identifiable genetic mutations. For one of those mutations, in a gene called SOD1, a targeted treatment now exists. Tofersen is an antisense oligonucleotide, a synthetic molecule that binds to the messenger RNA produced by the mutated SOD1 gene and reduces production of the toxic protein. In its pivotal trial, tofersen significantly reduced concentrations of SOD1 protein in cerebrospinal fluid and lowered neurofilament light chain levels in the blood, a signal that nerve damage was slowing.20PubMed. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS Real-world clinical experience with tofersen has confirmed these biomarker responses, with treated patients showing an average 62 percent reduction in blood neurofilament levels after five months.21PubMed. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice
The most common genetic cause of ALS is a repeat expansion in the C9orf72 gene, responsible for roughly 40 percent of familial cases and a smaller share of sporadic ones. This mutation produces both toxic RNA clusters and abnormal protein aggregates inside neurons. Several therapeutic strategies are in development: antisense oligonucleotides designed to target the repeat RNA, small molecules that stabilize DNA structures to prevent toxic transcription, and CRISPR-based gene editing approaches that aim to remove or silence the expanded repeat entirely.22PubMed Central. Therapeutic Approaches for C9ORF72-Related ALS: Current Strategies and Future Horizons None of these has reached approval yet, but the precedent set by tofersen in SOD1-ALS suggests the path is plausible.
Immune-Based and Regenerative Approaches
ALS is not purely a disease of motor neurons dying in isolation. The immune system plays a complicated dual role, sometimes protective and sometimes destructive. Research has increasingly focused on regulatory T cells, a type of immune cell that normally keeps inflammation in check. In ALS, lower numbers or impaired function of these cells correlate with faster disease progression.23Nature Communications. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression This has made regulatory T cells a prime therapeutic target, with approaches ranging from infusing expanded populations of the patient’s own regulatory T cells to engineering chimeric antigen receptor T cells that specifically home in on toxic protein aggregates associated with ALS.24PubMed Central. Human CD4+CD25+ T cells expressing a chimeric antigen receptor against aberrant superoxide dismutase 1 trigger antigen-specific immunomodulation
Stem cell therapy has also generated sustained interest. Mesenchymal stem cells, which can be harvested from bone marrow or other tissues, have anti-inflammatory and neurotrophic properties that make them attractive candidates. Multiple phase I and II trials have shown the approach is safe and tolerable, but functional improvements in patients remain modest so far.25PubMed. Cell therapy in ALS: An update on preclinical and clinical studies The field is moving toward stem cells that are engineered or selected to deliver growth factors at multiple points along the pathway from brain to muscle, rather than relying on a generic anti-inflammatory effect.25PubMed. Cell therapy in ALS: An update on preclinical and clinical studies
Tracking What You Cannot Feel Yet
One of the cruelest features of ALS is that by the time you notice a new symptom, the underlying nerve damage is already extensive. Biomarkers and digital tools are beginning to fill this gap, potentially allowing earlier treatment adjustments and better trial designs.
Neurofilament light chain, a protein released into blood and spinal fluid when nerve fibers degenerate, has emerged as the most promising blood-based biomarker. People with ALS have roughly four times the blood levels of healthy individuals, and those levels predict survival independently: patients in the highest third of neurofilament levels at diagnosis faced nearly four times the mortality risk of those in the lowest third.26PubMed Central. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis Because neurofilament levels stay relatively stable over time for a given person, a drop in levels after starting a new treatment is a strong signal that the drug is having a biological effect. This is exactly what happened with tofersen, and the biomarker is now being used to guide treatment decisions in clinical practice.27PubMed Central. Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal
Digital speech biomarkers represent another frontier. Standard clinical rating scales grade speech function in coarse steps, so a patient can score “normal” on the scale while measurable changes in speaking rate, syllable precision, and voice quality are already underway. Studies have shown that automated speech analysis can detect bulbar decline even when patient-reported scores remain unchanged.28Scientific Reports. Speech-based digital endpoints track ALS progression and align with standard clinical outcomes: evidence from the VRG50635 trial These tools can be used remotely, potentially replacing some clinic visits with at-home recordings and giving clinicians a more continuous picture of how someone is doing between appointments.29PubMed Central. Multimodal Speech Biomarkers for Remote Monitoring of ALS Disease Progression
Rare Reversals and What They Suggest
Most discussions of ALS assume relentless downward progression, and for the vast majority of patients, that is accurate. But a small number of documented cases describe something genuinely unusual: people who met diagnostic criteria for ALS and then improved, sometimes dramatically. A study examining these “ALS reversals” found that cases were more likely to be male, to have limb-onset disease, and, counterintuitively, to have progressed faster initially. The prevalence of co-existing myasthenia gravis and purely lower motor neuron disease was higher than expected. Certain supplements and medications, including curcumin, cannabidiol, vitamin D, and azathioprine, were more commonly reported by reversal cases than by controls.30PubMed. “ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities
These findings should be interpreted cautiously. Some reversals may reflect initial misdiagnosis: conditions that mimic ALS, such as certain autoimmune neuromuscular disorders, can resolve with treatment. Others may represent an extreme tail of the natural variability of ALS itself. The researchers did not claim that any specific supplement caused improvement, only that their use was more common among reversal cases. Still, the existence of these cases keeps alive the question of whether the disease is, in principle, reversible under the right conditions, and what those conditions might teach us about the biology of motor neuron survival.
Environmental Exposures and the Question of Prevention
Most ALS occurs sporadically, without a clear genetic cause, which raises the question of what environmental factors might contribute. A study that measured persistent pollutants directly in participants’ blood found significantly increased odds of ALS associated with certain pesticides and organochlorine compounds. Reported pesticide exposure carried roughly five times the odds of ALS; military service doubled the odds in some exposure windows.31JAMA Neurology. Association of Environmental Toxins With Amyotrophic Lateral Sclerosis Other factors that have been investigated include heavy metals, electrical injuries, strenuous physical activity, and smoking, though proving direct causation has remained elusive for all of them.32PubMed Central. Potential Environmental Factors in Amyotrophic Lateral Sclerosis
Emerging research has also turned to the gut microbiome. Studies in ALS patients have found reduced microbial diversity and loss of beneficial bacterial functions, correlated with intestinal inflammation and altered gut barrier integrity. The gut-microbiome-neuron axis is still a young research area, but it adds another layer to the picture of ALS as a disease influenced by multiple interacting systems rather than a single point of failure.
How the Pieces Fit Together
The research on non-cell-autonomous mechanisms of motor neuron death helps explain why so many different interventions can each contribute something. Motor neurons in ALS do not die solely because of an internal defect: surrounding cells, including astrocytes, secrete toxic factors that selectively kill them.33PubMed Central. Motor neuron death in ALS: programmed by astrocytes? This means the disease has multiple pressure points. Riluzole addresses excitotoxicity. Edaravone targets oxidative stress. Noninvasive ventilation buys time for the respiratory system. Nutrition counteracts the metabolic drain. Immune therapies aim to shift the inflammatory environment. Gene-targeted drugs reduce the toxic protein load in genetic cases. No single approach is sufficient, but stacking them has a cumulative effect that the research consistently supports.
The practical implication is that people with ALS benefit most from an aggressive, multi-pronged strategy initiated as early as possible. Getting into a specialized multidisciplinary clinic, starting riluzole, getting baseline respiratory and nutritional assessments, beginning a supervised exercise program, and pursuing genetic testing to see whether targeted therapies apply are all steps that can happen in the first weeks after diagnosis. Each one individually may contribute months; together, they can reshape the trajectory of the disease in ways that were not available even a decade ago.